# Meredith M. Regan

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/meredith-m-regan/

## Facts

| Field | Value |
| --- | --- |
| Citations | 41,383 |
| Field | Breast Cancer Treatment Studies |
| h-index | 95 |
| i10-index | 297 |
| Last Known Institution | Dana-Farber Cancer Institute |
| OpenAlex ID | https://openalex.org/A5017334876 |
| ORCID iD | https://orcid.org/0000-0002-2428-6109 |
| Works | 675 |

## Researcher papers

- [Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study](https://scholariq.org/papers/prognostic-factors-for-overall-survival-in-patients-with-metastatic-renal-cell/)
- [Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update](https://scholariq.org/papers/estrogen-and-progesterone-receptor-testing-in-breast-cancer-asco-cap-guideline/)
- [De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017](https://scholariq.org/papers/de-escalating-and-escalating-treatments-for-early-stage-breast-cancer-the-st/)
- [Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials](https://scholariq.org/papers/long-term-outcomes-for-neoadjuvant-versus-adjuvant-chemotherapy-in-early-breast/)
- [Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline](https://scholariq.org/papers/neoadjuvant-chemotherapy-endocrine-therapy-and-targeted-therapy-for-breast/)
- [Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up](https://scholariq.org/papers/early-breast-cancer-esmo-clinical-practice-guideline-for-diagnosis-treatment-and/)
- [The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer](https://scholariq.org/papers/the-8q24-cancer-risk-variant-rs6983267-shows-long-range-interaction-with-myc-in/)
- [Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial](https://scholariq.org/papers/pembrolizumab-plus-trastuzumab-in-trastuzumab-resistant-advanced-her2-positive/)
- [Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials](https://scholariq.org/papers/trastuzumab-for-early-stage-her2-positive-breast-cancer-a-meta-analysis-of-13/)
- [Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials](https://scholariq.org/papers/anthracycline-containing-and-taxane-containing-chemotherapy-for-early-stage/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Estrogen and related hormone effects](https://scholariq.org/topics/estrogen-and-related-hormone-effects/)
- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Prostate Cancer Diagnosis and Treatment](https://scholariq.org/topics/prostate-cancer-diagnosis-and-treatment/)

## Researcher university

- [Dana-Farber Cancer Institute](https://scholariq.org/institutions/dana-farber-cancer-institute/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.